SELLAS Life Sciences Group, a clinical stage biopharmaceutical company based in New York, develops immunotherapeutics for cancer, including galinpepimut-S and SLS009. The company went public in 2008 and employs 16 staff.
Jane Wasman bought 20,000 shares of SLS on 30 May at $1.69 per share, worth a total of $34K. They now own 30,400 SLS shares, or a 192% holding increase.
📡️ Health Care
Insider Trades
More Signals
Feature in Progress
This section is under development. Check back soon for updates!
